BioCryst Pharmaceuticals BCRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $874.84M+94.1% | $450.71M+36.0% | $331.41M+22.4% | $270.83M+72.3% | ||
| $19.08M+55.5% | $12.27M+174% | $4.48M-30.1% | $6.41M-11.4% | ||
| $855.76M+95.2% | $438.44M+34.1% | $326.93M+23.6% | $264.42M+76.3% | ||
| 97.8%+0.5pp | 97.3%-1.4pp | 98.6%+1.0pp | 97.6%+2.2pp | ||
| $166.13M-4.9% | $174.64M-19.4% | $216.57M-14.5% | $253.3M+21.3% | ||
| $348.65M+30.9% | $266.35M+24.4% | $214.07M+34.3% | $159.37M+34.1% | ||
| $533.85M+17.8% | $453.26M+4.2% | $435.12M+3.8% | $419.26M+25.2% | ||
| $340.99M+13,509% | -$2.54M+97.5% | -$103.71M+30.1% | -$148.44M+16.5% | ||
| 39%+39.5pp | -0.6%+30.7pp | -31.3%+23.5pp | -54.8%+58.3pp | ||
| $78.87M-19.9% | $98.52M-9.0% | $108.24M+9.2% | $99.09M+67.1% | ||
| -$73.6M+12.8% | -$84.41M+31.1% | -$122.52M-27.7% | -$95.95M-7,990% | ||
| $267.39M+408% | -$86.95M+61.6% | -$226.23M+7.4% | -$244.38M-34.4% | ||
| $3.53M+83.2% | $1.93M— | —— | $2.73M+21.3% | ||
| $263.86M+397% | -$88.88M+60.8% | -$226.54M+8.3% | -$247.12M-34.3% | ||
| 30.2%+49.9pp | -19.7%+48.6pp | -68.4%+22.9pp | -91.2%+25.9pp | ||
| $1.21+381% | -$0.43+63.6% | -$1.18+11.3% | -$1.33-29.1% | ||
| $342.38M+26,498% | -$1.3M+98.7% | -$102.05M+30.6% | -$147M+16.9% | ||
| 39.1%+39.4pp | -0.3%+30.5pp | -30.8%+23.5pp | -54.3%+58.3pp | ||
| $340.99M+13,509% | -$2.54M+97.5% | -$103.71M+30.1% | -$148.44M+16.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
